{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:07Z","timestamp":1740138487527,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02261-w","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T19:02:21Z","timestamp":1703790141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-1768","authenticated-orcid":false,"given":"Abas","family":"Sezer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-5009","authenticated-orcid":false,"given":"Lejla","family":"Mahmutovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-9963","authenticated-orcid":false,"given":"Bet\u00fcl","family":"Ak\u00e7e\u015fme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"2261_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","volume":"124","author":"L Sleire","year":"2017","unstructured":"Sleire L, F\u00f8rde HE, Netland IA, Leiss L, Skeie BS, Enger P\u00d8. Drug repurposing in cancer. Pharmacol Res. 2017;124:74\u201391. https:\/\/doi.org\/10.1016\/j.phrs.2017.07.013.","journal-title":"Pharmacol Res"},{"issue":"3","key":"2261_CR2","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769\u201392. https:\/\/doi.org\/10.3390\/cancers6031769.","journal-title":"Cancers"},{"key":"2261_CR3","unstructured":"Padala SA, Kallam A. Diffuse large B-cell lymphoma. In: StatPearls. Treasure Island: StatPearls Publishing; 2023 [cited 2023 Jun 15]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557796\/."},{"issue":"24","key":"2261_CR4","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.3390\/cancers13246384","volume":"13","author":"J Carreras","year":"2021","unstructured":"Carreras J, Hiraiwa S, Kikuti YY, Miyaoka M, Tomita S, Ikoma H, et al. Artificial neural networks predicted the overall survival and molecular subtypes of diffuse large B-cell lymphoma using a pancancer immune-oncology panel. Cancers. 2021;13(24):6384. https:\/\/doi.org\/10.3390\/cancers13246384.","journal-title":"Cancers"},{"issue":"21","key":"2261_CR5","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.3390\/cancers14215318","volume":"14","author":"J Carreras","year":"2022","unstructured":"Carreras J, Roncador G, Hamoudi R. Artificial intelligence predicted overall survival and classified mature B-cell neoplasms based on immuno-oncology and immune checkpoint panels. Cancers. 2022;14(21):5318. https:\/\/doi.org\/10.3390\/cancers14215318.","journal-title":"Cancers"},{"issue":"11","key":"2261_CR6","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229\u201353. https:\/\/doi.org\/10.1182\/blood.2022015851.","journal-title":"Blood"},{"key":"2261_CR7","unstructured":"Jamil A, Mukkamalla SKR. Lymphoma. In: StatPearls. Treasure Island: StatPearls Publishing, 2022 [cited 2022 Mar 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560826\/."},{"issue":"1","key":"2261_CR8","first-page":"34","volume":"101","author":"WD Lewis","year":"2020","unstructured":"Lewis WD, Lilly S, Jones KL. Lymphoma: diagnosis and treatment. Am Fam Physician. 2020;101(1):34\u201341.","journal-title":"Am Fam Physician"},{"key":"2261_CR9","unstructured":"National Cancer Institute. Non-Hodgkin lymphoma\u2014cancer stat facts. SEER. 18 March 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"issue":"14","key":"2261_CR10","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.3390\/cancers13143625","volume":"13","author":"C Bezombes","year":"2021","unstructured":"Bezombes C, P\u00e9rez-Gal\u00e1n P. Immunotherapies in non-Hodgkin\u2019s lymphoma. Cancers. 2021;13(14):3625. https:\/\/doi.org\/10.3390\/cancers13143625.","journal-title":"Cancers"},{"issue":"8","key":"2261_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/biomedicines10081960","volume":"10","author":"S Sheikh","year":"2022","unstructured":"Sheikh S, Migliorini D, Lang N. CAR T-based therapies in lymphoma: a review of current practice and perspectives. Biomedicines. 2022;10(8):1960. https:\/\/doi.org\/10.3390\/biomedicines10081960.","journal-title":"Biomedicines"},{"issue":"1","key":"2261_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cdtm.2018.02.001","volume":"4","author":"R Sun","year":"2018","unstructured":"Sun R, Yu Q, Young KH. Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. Chronic Dis Transl Med. 2018;4(1):29\u201344. https:\/\/doi.org\/10.1016\/j.cdtm.2018.02.001.","journal-title":"Chronic Dis Transl Med"},{"issue":"13","key":"2261_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1182\/blood.2020006784","volume":"138","author":"W Xu","year":"2021","unstructured":"Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021;138(13):1110\u20139. https:\/\/doi.org\/10.1182\/blood.2020006784.","journal-title":"Blood"},{"issue":"4","key":"2261_CR14","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3892\/ol.2020.11394","volume":"19","author":"Y Gu","year":"2020","unstructured":"Gu Y, Mohammad IS, Liu Z. Overview of the STAT-3 signaling pathway in cancer and the development of specific inhibitors. Oncol Lett. 2020;19(4):2585\u201394. https:\/\/doi.org\/10.3892\/ol.2020.11394.","journal-title":"Oncol Lett"},{"issue":"2","key":"2261_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young RM, Shaffer AL, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):77\u201385. https:\/\/doi.org\/10.1053\/j.seminhematol.2015.01.008.","journal-title":"Semin Hematol"},{"issue":"6","key":"2261_CR16","doi-asserted-by":"publisher","first-page":"a000109","DOI":"10.1101\/cshperspect.a000109","volume":"2","author":"LM Staudt","year":"2010","unstructured":"Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6):a000109. https:\/\/doi.org\/10.1101\/cshperspect.a000109.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"2261_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/cells7110189","volume":"7","author":"R Kennedy","year":"2018","unstructured":"Kennedy R, Klein U. Aberrant activation of NF-\u03baB signalling in aggressive lymphoid malignancies. Cells. 2018;7(11):189. https:\/\/doi.org\/10.3390\/cells7110189.","journal-title":"Cells"},{"issue":"5","key":"2261_CR18","first-page":"433","volume":"3","author":"TP Chang","year":"2013","unstructured":"Chang TP, Vancurova I. NF\u03baB function and regulation in cutaneous T-cell lymphoma. Am J Cancer Res. 2013;3(5):433\u201345.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2261_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-018-0621-5","volume":"11","author":"S Balaji","year":"2018","unstructured":"Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M. NF-\u03baB signaling and its relevance to the treatment of mantle cell lymphoma. J Hematol OncolJ Hematol Oncol. 2018;11(1):83. https:\/\/doi.org\/10.1186\/s13045-018-0621-5.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"2","key":"2261_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/biomedicines6020059","volume":"6","author":"P Roy","year":"2018","unstructured":"Roy P, Sarkar UA, Basak S. The NF-\u03baB activating pathways in multiple myeloma. Biomedicines. 2018;6(2):59. https:\/\/doi.org\/10.3390\/biomedicines6020059.","journal-title":"Biomedicines"},{"issue":"2","key":"2261_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/biomedicines6020038","volume":"6","author":"P Grondona","year":"2018","unstructured":"Grondona P, Bucher P, Schulze-Osthoff K, Hailfinger S, Schmitt A. NF-\u03baB activation in lymphoid malignancies: genetics, signaling, and targeted therapy. Biomedicines. 2018;6(2):38. https:\/\/doi.org\/10.3390\/biomedicines6020038.","journal-title":"Biomedicines"},{"key":"2261_CR22","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. https:\/\/doi.org\/10.1038\/sigtrans.2017.23.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2261_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020;5(1):209. https:\/\/doi.org\/10.1038\/s41392-020-00312-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2261_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC. Non-canonical NF-\u03baB signaling pathway. Cell Res. 2011;21(1):71\u201385. https:\/\/doi.org\/10.1038\/cr.2010.177.","journal-title":"Cell Res"},{"issue":"1","key":"2261_CR25","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1038\/s41467-018-06573-8","volume":"9","author":"F Schlauderer","year":"2018","unstructured":"Schlauderer F, Seeholzer T, Desfosses A, Gehring T, Strauss M, Hopfner KP, et al. Molecular architecture and regulation of BCL10-MALT1 filaments. Nat Commun. 2018;9(1):4041. https:\/\/doi.org\/10.1038\/s41467-018-06573-8.","journal-title":"Nat Commun"},{"issue":"12","key":"2261_CR26","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1515\/hsz-2016-0216","volume":"397","author":"I Meininger","year":"2016","unstructured":"Meininger I, Krappmann D. Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. Biol Chem. 2016;397(12):1315\u201333. https:\/\/doi.org\/10.1515\/hsz-2016-0216.","journal-title":"Biol Chem"},{"issue":"3","key":"2261_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/s1097-2765(04)00236-9","volume":"14","author":"L Sun","year":"2004","unstructured":"Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell. 2004;14(3):289\u2013301. https:\/\/doi.org\/10.1016\/s1097-2765(04)00236-9.","journal-title":"Mol Cell"},{"issue":"1","key":"2261_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/cmi.2017.77","volume":"15","author":"L Isra\u00ebl","year":"2018","unstructured":"Isra\u00ebl L, Bornancin F. Ways and waves of MALT1 paracaspase activation. Cell Mol Immunol. 2018;15(1):8\u201311. https:\/\/doi.org\/10.1038\/cmi.2017.77.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2261_CR29","doi-asserted-by":"publisher","first-page":"e0169026","DOI":"10.1371\/journal.pone.0169026","volume":"12","author":"S Ginster","year":"2017","unstructured":"Ginster S, Bardet M, Unterreiner A, Malinverni C, Renner F, Lam S, et al. Two antagonistic MALT1 auto-cleavage mechanisms reveal a role for TRAF6 to unleash MALT1 activation. PLoS ONE. 2017;12(1):e0169026. https:\/\/doi.org\/10.1371\/journal.pone.0169026.","journal-title":"PLoS ONE"},{"issue":"8","key":"2261_CR30","doi-asserted-by":"publisher","first-page":"e103774","DOI":"10.1371\/journal.pone.0103774","volume":"9","author":"M Baens","year":"2014","unstructured":"Baens M, Bonsignore L, Somers R, Vanderheydt C, Weeks SD, Gunnarsson J, et al. MALT1 auto-proteolysis is essential for NF-\u03baB-dependent gene transcription in activated lymphocytes. PLoS ONE. 2014;9(8):e103774. https:\/\/doi.org\/10.1371\/journal.pone.0103774.","journal-title":"PLoS ONE"},{"issue":"3","key":"2261_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00018-015-2059-z","volume":"73","author":"M Jaworski","year":"2016","unstructured":"Jaworski M, Thome M. The paracaspase MALT1: biological function and potential for therapeutic inhibition. Cell Mol Life Sci. 2016;73(3):459\u201373. https:\/\/doi.org\/10.1007\/s00018-015-2059-z.","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"2261_CR32","doi-asserted-by":"publisher","first-page":"1008893","DOI":"10.3389\/fnut.2022.1008893","volume":"26","author":"OO Izuegbuna","year":"2022","unstructured":"Izuegbuna OO. Polyphenols: chemoprevention and therapeutic potentials in hematological malignancies. Front Nutr. 2022;26(9):1008893. https:\/\/doi.org\/10.3389\/fnut.2022.1008893.","journal-title":"Front Nutr"},{"issue":"3","key":"2261_CR33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jpha.2021.07.002","volume":"12","author":"A Chauhan","year":"2022","unstructured":"Chauhan A, Islam AU, Prakash H, Singh S. Phytochemicals targeting NF-\u03baB signaling: potential anti-cancer interventions. J Pharm Anal. 2022;12(3):394\u2013405. https:\/\/doi.org\/10.1016\/j.jpha.2021.07.002.","journal-title":"J Pharm Anal"},{"issue":"3","key":"2261_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"G Madhavi Sastry","year":"2013","unstructured":"Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221\u201334. https:\/\/doi.org\/10.1007\/s10822-013-9644-8.","journal-title":"J Comput Aided Mol Des"},{"issue":"1","key":"2261_CR35","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717. https:\/\/doi.org\/10.1038\/srep42717.","journal-title":"Sci Rep"},{"issue":"1","key":"2261_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/jop.2021.0069","volume":"38","author":"TK Karami","year":"2022","unstructured":"Karami TK, Hailu S, Feng S, Graham R, Gukasyan HJ. Eyes on lipinski\u2019s rule of five: a new, \u201crule of thumb\u201d for physicochemical design space of ophthalmic drugs. J Ocul Pharmacol Ther. 2022;38(1):43\u201355. https:\/\/doi.org\/10.1089\/jop.2021.0069.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"2261_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/cc9800071","volume":"1","author":"AK Ghose","year":"1999","unstructured":"Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery 1: a qualitative and quantitative characterization of known drug databases. J Comb Chem. 1999;1(1):55\u201368. https:\/\/doi.org\/10.1021\/cc9800071.","journal-title":"J Comb Chem"},{"issue":"12","key":"2261_CR38","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615\u201323. https:\/\/doi.org\/10.1021\/jm020017n.","journal-title":"J Med Chem"},{"issue":"21","key":"2261_CR39","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1021\/jm000292e","volume":"43","author":"WJ Egan","year":"2000","unstructured":"Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000;43(21):3867\u201377. https:\/\/doi.org\/10.1021\/jm000292e.","journal-title":"J Med Chem"},{"issue":"17","key":"2261_CR40","doi-asserted-by":"publisher","first-page":"6617","DOI":"10.1080\/07391102.2020.1796812","volume":"39","author":"R Yadav","year":"2021","unstructured":"Yadav R, Imran M, Dhamija P, Chaurasia DK, Handu S. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2. J Biomol Struct Dyn. 2021;39(17):6617\u201332. https:\/\/doi.org\/10.1080\/07391102.2020.1796812.","journal-title":"J Biomol Struct Dyn"},{"key":"2261_CR41","unstructured":"Grogan S, Preuss CV. Pharmacokinetics. In: StatPearls. Treasure Island: StatPearls Publishing; 2023 [cited 2023 Jun 11]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557744\/."},{"issue":"1","key":"2261_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1021\/acs.molpharmaceut.7b00957","volume":"15","author":"ER Samuels","year":"2018","unstructured":"Samuels ER, Sevrioukova I. Inhibition of human CYP3A4 by rationally designed ritonavir-like compounds: impact and interplay of the side group functionalities. Mol Pharm. 2018;15(1):279\u201388. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00957.","journal-title":"Mol Pharm"},{"issue":"10","key":"2261_CR43","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1172\/JCI99436","volume":"128","author":"L Font\u00e1n","year":"2018","unstructured":"Font\u00e1n L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J Clin Invest. 2018;128(10):4397\u2013412. https:\/\/doi.org\/10.1172\/JCI99436.","journal-title":"J Clin Invest"},{"issue":"11","key":"2261_CR44","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1084\/jem.20091167","volume":"206","author":"U Ferch","year":"2009","unstructured":"Ferch U, Kloo B, Gewies A, Pf\u00e4nder V, D\u00fcwel M, Peschel C, et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell\u2013like diffuse large B cell lymphoma cells. J Exp Med. 2009;206(11):2313\u201320. https:\/\/doi.org\/10.1084\/jem.20091167.","journal-title":"J Exp Med"},{"issue":"31","key":"2261_CR45","doi-asserted-by":"publisher","first-page":"31216","DOI":"10.18632\/oncotarget.5157","volume":"6","author":"S Shukla","year":"2015","unstructured":"Shukla S, Kanwal R, Shankar E, Datt M, Chance MR, Fu P, et al. Apigenin blocks IKK\u03b1 activation and suppresses prostate cancer progression. Oncotarget. 2015;6(31):31216\u201332. https:\/\/doi.org\/10.18632\/oncotarget.5157.","journal-title":"Oncotarget"},{"issue":"1","key":"2261_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.toxlet.2013.10.007","volume":"224","author":"DG Wu","year":"2014","unstructured":"Wu DG, Yu P, Li JW, Jiang P, Sun J, Wang HZ, et al. Apigenin potentiates the growth inhibitory effects by IKK-\u03b2-mediated NF-\u03baB activation in pancreatic cancer cells. Toxicol Lett. 2014;224(1):157\u201364. https:\/\/doi.org\/10.1016\/j.toxlet.2013.10.007.","journal-title":"Toxicol Lett"},{"issue":"6","key":"2261_CR47","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/nu11061397","volume":"11","author":"SC Liao","year":"2019","unstructured":"Liao SC, Hsu HW, Chuang KL, Huang ZY, Lin KT, Hsu WH, et al. Using the pleiotropic characteristics of curcumin to validate the potential application of a novel gene expression screening platform. Nutrients. 2019;11(6):1397. https:\/\/doi.org\/10.3390\/nu11061397.","journal-title":"Nutrients"},{"issue":"2","key":"2261_CR48","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.intimp.2011.12.009","volume":"12","author":"A Olivera","year":"2012","unstructured":"Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, et al. Inhibition of the NF-\u03baB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol. 2012;12(2):368\u201377. https:\/\/doi.org\/10.1016\/j.intimp.2011.12.009.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2261_CR49","doi-asserted-by":"publisher","first-page":"e53101","DOI":"10.1371\/journal.pone.0053101","volume":"7","author":"G Ji","year":"2012","unstructured":"Ji G, Zhang Y, Yang Q, Cheng S, Hao J, Zhao X, et al. Genistein suppresses LPS-induced inflammatory response through inhibiting NF-\u03baB following AMP kinase activation in RAW 264.7 macrophages. PLoS ONE. 2012;7(12):e53101. https:\/\/doi.org\/10.1371\/journal.pone.0053101.","journal-title":"PLoS ONE"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02261-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T10:21:08Z","timestamp":1704709268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02261-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02261-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2023,12,28]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"37"}}